Deal Watch: Millendo Completes Merger With OvaScience, With $85m In Bank For Two Mid-Stage Programs
OvaScience’s cash plus a $49.5m venture capital raise leave Millendo with more than enough to get two current programs to data readouts in early 2020, company says. AMAG merges with Perosphere, adding to its hematology business.
You may also be interested in...
Biogen is paying around $800m cash to buy UK-based Nightstar Therapeutics, which focuses on gene therapy for retinal diseases.
After much turmoil in 2018, the biopharma sector in China is embracing multiple uncertainties in the year of the boar.
Eli Lilly signed a licensing deal to develop a tau aggregation inhibitor small molecule for Alzheimer's disease – a drug that works differently from existing antibodies and could offer potential in combination regimens. AC Immune CEO Andrea Pfeifer talked to Scrip about the deal.